TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume

  • TherapeuticsMD Inc TXMD reported a Q1 EPS loss of $0.11 better than the analyst consensus estimate loss of $0.12, as well as an improvement from EPS loss of $0.21 a year ago. Sales of $19.90 million were slightly better than the consensus of $19.77 million.
  • Though the sales figure improved 60% Y/Y, it was down 13% sequentially.
  • Annovera's net product revenue increased to $8.8 million compared to $2.3 million a year ago.
  • Net revenue per unit was $1,071. The company expects net revenue per unit for Annovera to average approximately $1,100 for the year.
  • Approximately 6,240 prescriptions were dispensed to patients during Q1, up 164% on a Y/Y basis and 5% sequentially.
  • Imvexxy revenue increased by 10% Y/Y to $7 million. Net revenue per unit reached $61, reflecting a 39% Y/Y improvement.
  • Approximately 108,200 prescriptions were dispensed, with the total prescription volume declined 14% Y/Y.
  • BIJUVA sales more than doubled to $2.5 million, with revenue per unit improving 85% Y/Y to approximately $69. Roughly 30,800 BIJUVA prescriptions were dispensed.
  • Gross margin of 76% was 2% lower than 78% reported a year ago, affected by production-related write-offs for Annovera of $0.9 million.
  • TherapeuticsMD held cash of $137.6 million at the end of Q1.
  • Price Action: TXMD shares dropped 10.9% at $1.14 in the market trading session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!